Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management

The study on selumetinib in 20 pediatric patients with Neurofibromatosis Type 1 (NF1) reveals significant dermatologic adverse effects, including xerosis, paronychia, acneiform rash, and hair abnormalities, impacting treatment adherence and quality of life. Xerosis affected 70% of patients, acneiform rash 55%, and hair abnormalities 70%, with females more prone to hair issues. These side effects led to treatment suspension in 20% of cases, causing tumor rebound in 75% of those. The study underscores the need for tailored management strategies to ensure effective treatment, highlighting the importance of addressing these adverse effects to maintain therapy efficacy and patient quality of life.